BriaCell Therapeutics Corp. (BCTX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended October 31, 2025 (Fiscal Q1 2026). BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology biotechnology company focused on developing targeted immunotherapies. Key programs include Bria-IMT (advancing to Phase 3 in metastatic breast cancer under FDA Fast Track designation) and Bria-OTS (personalized off-the-shelf immunotherapy). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 (Oct 31, 2025) | Q1 2025 (Oct 31, 2024) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,278,328) | $(5,829,276) |
| Net Loss Per Share (Basic & Diluted) | $(4.35) | $(32.67) |
| Operating Expenses | $8,322,943 | $5,152,832 |
| Cash and Cash Equivalents | $2,714,012 | $5,792,265 |
| Short-term Investments | $7,461,960 | $N/A (Not reported separately in prior period) |
| Total Assets | $13,075,050 | $N/A |
| Working Capital | $8,030,634 | $N/A |
| Accumulated Deficit | $(119,953,129) | $(91,245,872) |
Note: The filing does not provide a clear comparative total asset or working capital figure for the prior year period in the summary tables, though the current period shows a positive working capital balance.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $2.45 million year-over-year, driven primarily by a 82% increase in Research and Development (R&D) expenses ($6.68M vs. $3.67M).
- R&D Spend Drivers: Clinical trial costs for the Bria-IMT Phase 3 study rose to $3.79M (from $2.45M), and Bria-OTS Phase 1/2a costs surged to $988k (from $78k) as the program entered clinical trials.
- Cash Burn: Cash and cash equivalents decreased by $7.78M during the quarter. Net cash used in operating activities was $7.70M.
- Financial Income: Net financial income improved significantly to $158,646 (from $11,714), aided by an $89,487 unrealized gain on short-term investments and higher interest income.
- Share Count: The company executed reverse stock splits (1-for-15 in Jan 2025 and 1-for-10 in Aug 2025). Outstanding shares are 1,883,906.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that the company's ability to continue as a going concern is dependent on its ability to raise additional capital. The accumulated deficit and negative cash flows cast "substantial doubt" on the company's ability to continue operations without further financing.
- Clinical Progress:
- Bria-IMT: 79 clinical sites are enrolling patients. Top-line data is expected in the first half of 2026. The Data Safety Monitoring Board (DSMB) issued a fourth consecutive positive recommendation with no safety concerns.
- Bria-OTS: Accepted into Memorial Sloan Kettering's Therapeutics Accelerator program. Preclinical data presented at SITC 2025 showed durable anti-cancer activity.
- Funding: The company received a $2.0M SBIR grant from the NCI for Bria-PROS+ in August 2025. No equity financing occurred during this quarter.
- Risks: Primary risks include the need for additional capital, the uncertainty of clinical trial outcomes, and the potential inability to achieve profitability.
Key Facts for Investor Verification
- Liquidity Runway: Verify the current cash burn rate against the $2.7M cash on hand and $7.5M in short-term investments to estimate the runway before additional financing is required.
- Phase 3 Milestones: Confirm the timeline for the Bria-IMT Phase 3 top-line data (expected H1 2026) and the specific event accrual requirements.
- Capital Raise Plans: Investigate any announced or planned equity/debt offerings to address the "substantial doubt" regarding the going concern status.
- Warrant Liability: Note the $406,873 warrant liability, which fluctuates based on stock price volatility and could impact future earnings.
- Reverse Split Impact: Ensure analysis of share-based compensation and per-share metrics accounts for the 1-for-150 aggregate reverse split adjustments.